Ixekizumab and ustekinumab in psoriasis: post-hoc comparison of onset and duration of treatment response

被引：2

作者：

Radtke, Marc ^{[1
]}

Conrad, Curdin ^{[2
]}

Schuster, Christopher ^{[3
,4
]}

Saure, Daniel ^{[3
]}

Mert, Can ^{[5
]}

Riedl, Elisabeth ^{[3
,4
]}

Costanzo, Antonio ^{[6
,7
]}

机构：

[1] Dermatol Hamburg GmbH, Hamburg, Germany

[2] CHU Vaudois, Lausanne, Switzerland

[3] Eli Lilly & Co, Indianapolis, IN 46285 USA

[4] Med Univ Vienna, Dept Dermatol, Vienna, Austria

[5] HaaPacs GmbH, Schriesheim, Germany

[6] Humanitas Univ, Milan, Italy

[7] IRCCS Humanitas Res Hosp, Milan, Italy

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2022年 / 33卷 / 02期

关键词：

D O I：

10.1080/09546634.2020.1782317

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：1168 / 1170

页数：3

共 50 条

[21] Ustekinumab demonstrates rapid onset of efficacy in the treatment of moderate-to-severe psoriasis
Rich, P.
Feldman, S.
Vender, R.
Ortonne, J. P.
Rustin, M.
Kunynetz, R.
Yeilding, N.
Fakharzadeh, S.
Li, S.
Prinz, J.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 18 - 18
[22] ON THE UTILITY OF A POST-HOC CORRECTION PROCEDURE FOR ONE-ZERO SAMPLING DURATION ESTIMATES
SUEN, HK
PRIMATES, 1986, 27 (02) : 237 - 244
[23] Efficacy Response in CF Patients Treated With Ivacaftor: Post-Hoc Analysis
Konstan, Michael W.
Plant, Barry J.
Elborn, J. Stuart
Rodriguez, Sally
Munck, Anne
Ahrens, Richard
Johnson, Charles
PEDIATRIC PULMONOLOGY, 2015, 50 (05) : 447 - 455
[24] Mixed treatment comparison of infliximab with ustekinumab in patients with moderate to severe psoriasis
Fan, T.
Bennett, H.
Smith, N.
Marin, M.
Shuvayu, S.
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E38 - E39
[25] Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS
Seyger, M. M. B.
Reich, A.
El Baou, C.
Schuster, C.
Riedl, E.
Paller, A. S.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (12) : E911 - E913
[26] Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials
Atul Deodhar
Andrew Blauvelt
Mark Lebwohl
Meghan Feely
Andris Kronbergs
Nadezhda Eberhart
Danting Zhu
Elsa Inman
Elsie Grace
Thorsten Holzkaemper
Proton Rahman
Helena Marzo-Ortega
Kim A. Papp
Joseph F. Merola
Alice B. Gottlieb
Sergio Schwartzman
Arthritis Research & Therapy, 26
[27] Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
Lebwohl, Mark
Deodhar, Atul
Schwartzman, Sergio
Salvarani, Carlo
Feely, Meghan
Zhu, Danting
Rahman, Proton
Papp, Kim A.
Merola, Joseph F.
Gottlieb, Alice
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB191 - AB191
[28] Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT
Maksymowych, Walter P.
Lambert, Robert
Krishnan, Eswar
Zhu, Baojin
Bolce, Rebecca
Ostergaard, Mikkel
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 5062 - 5065
[29] Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials
Deodhar, Atul
Blauvelt, Andrew
Lebwohl, Mark
Feely, Meghan
Kronbergs, Andris
Eberhart, Nadezhda
Zhu, Danting
Inman, Elsa
Grace, Elsie
Holzkaemper, Thorsten
Rahman, Proton
Marzo-Ortega, Helena
Papp, Kim A.
Merola, Joseph F.
Gottlieb, Alice B.
Schwartzman, Sergio
ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
[30] COST-EFFECTIVENESS COMPARISON OF RISANKIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF SEVERE PSORIASIS
Dzik, M.
Nadzieja-Koziol, A.
Owczarek, W.
VALUE IN HEALTH, 2019, 22 : S423 - S423

← 1 2 3 4 5 →